Parkinson’s disease is a progressive brain disorder that gradually destroys the nerve cells responsible for coordinating movement. It affects roughly 149 per 100,000 people worldwide, and that number is climbing fast: projections estimate 25.2 million people will be living with the disease by 2050, more than double the 2021 figure. While most people associate Parkinson’s with tremor, the disease reaches far beyond shaking hands, affecting sleep, mood, digestion, and thinking over time.
What Happens in the Brain
Deep inside the brain sits a small cluster of neurons called the substantia nigra. These neurons produce dopamine, a chemical messenger that travels to a region called the basal ganglia, where it fine-tunes voluntary movement. Every time you reach for a glass of water or take a step, dopamine from the substantia nigra helps make that motion smooth and controlled.
In Parkinson’s disease, these dopamine-producing neurons progressively die off. As they disappear, less dopamine reaches the basal ganglia, and the brain loses its ability to coordinate movement properly. By the time the first motor symptoms appear, a substantial portion of these neurons has already been lost.
The underlying culprit appears to be a protein called alpha-synuclein. Normally present in healthy neurons, this protein misfolds and clumps together in a stepwise process, first forming small clusters, then larger fibrous tangles, and eventually dense deposits called Lewy bodies. These protein clumps are the pathological hallmark of Parkinson’s, found in the brains of nearly everyone with the disease. The accumulation of these deposits is thought to poison neurons from the inside, driving the progressive cell death that defines the condition.
Who Gets Parkinson’s and Why
Parkinson’s results from a mix of genetic susceptibility and environmental exposures, though the environment plays the dominant role. Purely genetic causes account for only about 2% of cases, and even the most common genetic risk factors have low penetrance, meaning most people who carry those mutations never develop the disease. Mutations in a gene called LRRK2 are found in 2 to 3% of people with Parkinson’s but only lead to the disease in 25 to 43% of carriers. Variants in another gene, GBA, are more common risk factors but have penetrance of just 10 to 20%.
Environmental toxicants carry clearer links. Pesticides have the strongest established relationship. A landmark 2011 study found that exposure to the pesticides rotenone and paraquat each roughly doubled the risk of developing Parkinson’s (odds ratio of 2.5 for both). The risk isn’t limited to farmworkers; people living near areas where pesticides are applied also face elevated risk. Beyond pesticides, the industrial solvent trichloroethylene (a common degreaser and dry-cleaning chemical) and air pollution are both implicated as likely contributors. Notably, many of the genes linked to Parkinson’s interact directly with these environmental toxicants, suggesting that genetics may determine who is vulnerable to chemical exposures rather than causing the disease on its own.
Early Warning Signs Before Movement Problems
Parkinson’s often announces itself years before the characteristic tremor appears, through a set of non-motor symptoms that are easy to overlook or attribute to aging. Loss of smell is one of the earliest and most common. Constipation that develops without a clear dietary explanation is another frequent early sign. Depression can precede motor symptoms by a decade or more.
A particularly telling early indicator is REM sleep behavior disorder, a condition where people physically act out their dreams, sometimes thrashing, kicking, or shouting during sleep. Not everyone with this sleep disorder develops Parkinson’s, but a significant percentage eventually do. Subtle changes in vision, drops in blood pressure upon standing (causing lightheadedness), urinary urgency, and mild cognitive shifts may also be present in these early stages.
The Four Cardinal Motor Symptoms
Once the disease progresses far enough, four primary movement symptoms emerge:
- Tremor typically starts in one hand and has a distinctive rhythmic, back-and-forth quality. It often looks like the person is rolling a pill between their thumb and forefinger. The tremor is most noticeable when the hand is resting and tends to lessen during intentional movement. It usually disappears during sleep.
- Rigidity means the muscles stay tense and contracted, making the body feel stiff and achy. If someone else tries to move the person’s arm, it moves in short, ratcheting jerks rather than smoothly.
- Bradykinesia is a general slowing of movement. Tasks that used to be automatic, like buttoning a shirt or brushing teeth, take noticeably longer. Facial muscles are affected too, creating a “masked” expression where the face appears blank or emotionless even when the person feels engaged.
- Postural instability develops as balance deteriorates, making falls increasingly likely. This symptom tends to appear later than the other three.
These symptoms usually begin on one side of the body and gradually spread to both sides over time.
How Parkinson’s Is Diagnosed
There is no single blood test or brain scan that definitively confirms Parkinson’s. Diagnosis remains clinical, meaning it is based on a neurologist’s examination. The Movement Disorder Society’s diagnostic criteria require the presence of bradykinesia plus either resting tremor or rigidity as the core finding. From there, clinicians look for supportive features that increase diagnostic confidence and “red flags” that might point to a different condition entirely.
Two levels of certainty are used: “clinically established” Parkinson’s (a high-confidence diagnosis) and “probable” Parkinson’s (where the evidence is strong but less definitive). Because early symptoms can mimic other conditions, it sometimes takes time and repeat evaluations before a firm diagnosis is made. How a person responds to dopamine-replacement medication often serves as an important clue, since Parkinson’s symptoms typically improve with treatment while similar-looking conditions may not.
How the Disease Progresses
Parkinson’s progression varies enormously from person to person, but clinicians use a five-stage scale to describe the general trajectory. In Stage 1, symptoms affect only one side of the body and are often mild enough to be inconvenient rather than disabling. Stage 2 brings symptoms to both sides, though balance remains intact. By Stage 3, balance problems emerge but the person can still live independently. Stage 4 involves severe disability, though walking and standing without assistance are still possible. Stage 5, the most advanced, typically means the person is wheelchair-bound or bedridden without help.
The pace of this progression differs widely. Some people remain in the early stages for many years. Others experience a faster decline, particularly those diagnosed at an older age or those whose disease features prominent balance problems early on.
Medication and the Dopamine Replacement Challenge
The most effective treatment for Parkinson’s motor symptoms replaces the missing dopamine. The brain can’t absorb dopamine directly from a pill because it can’t cross from the bloodstream into the brain. But a precursor molecule called levodopa can make that crossing. Once inside the brain, levodopa converts into dopamine, compensating for the neurons that have been lost. It’s typically combined with a second drug that prevents levodopa from converting too early (outside the brain), ensuring more of it reaches where it’s needed.
For most people, levodopa works remarkably well in the early years. Movement becomes smoother, stiffness eases, and daily tasks get easier. The challenge comes with time. After 5 to 10 years on levodopa, roughly half of patients develop motor complications. These can include “wearing off” periods where the medication stops working before the next dose is due, and involuntary, sometimes fluid movements called dyskinesias. Managing these fluctuations becomes a central part of treatment as the disease advances, often requiring careful adjustment of medication timing and dosing.
Deep Brain Stimulation
For people whose motor symptoms respond well to medication but who struggle with severe fluctuations or dyskinesias, deep brain stimulation (DBS) is an option. The procedure involves implanting thin electrodes into a specific brain region and connecting them to a small device (similar to a pacemaker) placed under the skin near the collarbone. The device delivers continuous electrical pulses that help regulate the abnormal brain signals causing movement problems.
DBS candidates are typically people who have had Parkinson’s for at least five years, whose symptoms still respond to dopamine medication (confirming the diagnosis), and who experience more than six hours a day of poor motor function despite treatment. In clinical studies, motor scores improved by about 51% in the first year after surgery. By year five, improvement settled to around 36%, reflecting the fact that DBS does not stop the underlying disease from progressing. It does, however, significantly reduce the time spent in “off” states and can allow people to lower their medication doses.
Non-Motor Symptoms Over Time
As Parkinson’s advances, non-motor symptoms often become more burdensome than the movement problems themselves. Cognitive changes can range from mild difficulties with attention and multitasking to, in some cases, dementia in later stages. Depression and anxiety are common throughout the disease course and are thought to stem from the same brain changes driving the motor symptoms, not simply from the emotional burden of living with a chronic illness.
Autonomic dysfunction, where the nervous system struggles to regulate automatic body functions, creates a range of daily challenges: blood pressure drops upon standing, excessive sweating, bladder urgency and frequency, and erectile dysfunction. Sleep disturbances go well beyond REM sleep behavior disorder to include insomnia, excessive daytime sleepiness, and fragmented sleep. These non-motor features vary widely between individuals but tend to accumulate as the disease progresses, making comprehensive management important for quality of life.